ARROWHEAD PHARMACEUTICALS ($ARWR) is expected to release its quarterly earnings data on Tuesday, November 25th after market close, per Finnhub. Analysts are expecting revenue of $179,379,464 and earnings of -$0.25 per share.
You can see Quiver Quantitative's $ARWR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARROWHEAD PHARMACEUTICALS Insider Trading Activity
ARROWHEAD PHARMACEUTICALS insiders have traded $ARWR stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
- JAMES C HAMILTON (Chief Medical Officer) has made 0 purchases and 5 sales selling 60,000 shares for an estimated $1,725,000.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ARROWHEAD PHARMACEUTICALS Hedge Fund Activity
We have seen 171 institutional investors add shares of ARROWHEAD PHARMACEUTICALS stock to their portfolio, and 152 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRIEHAUS CAPITAL MANAGEMENT LLC added 2,099,398 shares (+inf%) to their portfolio in Q3 2025, for an estimated $72,408,237
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 2,017,489 shares (+3142.5%) to their portfolio in Q3 2025, for an estimated $69,583,195
- DEERFIELD MANAGEMENT COMPANY, L.P. added 993,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $34,248,570
- JANUS HENDERSON GROUP PLC added 923,722 shares (+1853.2%) to their portfolio in Q3 2025, for an estimated $31,859,171
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 834,661 shares (+31.1%) to their portfolio in Q3 2025, for an estimated $28,787,457
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 822,343 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $28,362,610
- BLACKROCK, INC. added 799,938 shares (+4.1%) to their portfolio in Q3 2025, for an estimated $27,589,861
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARROWHEAD PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ARWR in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 11/19/2025
- Piper Sandler issued a "Overweight" rating on 11/19/2025
- RBC Capital issued a "Outperform" rating on 11/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/08/2025
To track analyst ratings and price targets for ARROWHEAD PHARMACEUTICALS, check out Quiver Quantitative's $ARWR forecast page.
ARROWHEAD PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 6 analysts offer price targets for $ARWR in the last 6 months, with a median target of $56.0.
Here are some recent targets:
- Andrea Tan from Goldman Sachs set a target price of $48.0 on 11/20/2025
- Edward Tenthoff from Piper Sandler set a target price of $70.0 on 11/19/2025
- Keay Nakae from Chardan Capital set a target price of $60.0 on 11/19/2025
- Luca Issi from RBC Capital set a target price of $52.0 on 11/19/2025
- Michael Ulz from Morgan Stanley set a target price of $45.0 on 11/12/2025
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $80.0 on 10/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
